All In Biotech

Drug Trial Radar · NCT06381661

Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Jul 9, 2026

Primary completion

Aug 9, 2028

Study completion Jul 9, 2031

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 37 weeks
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.

Conditions

  • Sepsis

Interventions

  • TocilizumabDrug

    8 mg per kilogram of body weight enterally (oral or via a gastric tube) once daily for 14 days (or hospital discharge pending which will occur first) (same for adults and children)

  • BaricitinibDrug

    4mg, enterally (oral or via a gastric tube) once daily for 14 days (or hospital discharge pending which will occur first) (same for adults and children)

  • AnakinraDrug

    100 mg subcutaneously once daily for 10 days (or hospital discharge pending which will occur first) (same for adults and children)

  • HydrocortisoneDrug

    50mg (in children: 1-2 mg/kg) IV Q6 for 7 days

  • Hydrocortisone and fludrocortisoneDrug

    Hydrocortisone 50mg IV Q6 for 7 days + Fludrocortisone 50mg orally or via gastric tube once a day for 7 days.

  • HeparinDrug

    Therapeutic unfractionated heparin (UFH) starting at 400 (in children: 20 IU/kg/h) IU/kg/24h (target between 0.3 and 0.5 IU/ml), adapted to the therapeutic Partial Thromboplastin Time targeting values in the range of 60 to 100 seconds, with lower intensity dosing in the range of 60 to 80 seconds, for 7 days (or ICU discharge, pending which will occur first).

  • Low molecular weight heparinDrug

    Therapeutic low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: 175 (in children 100 U/kg) IU/kg/24h, for 7 days (or hospital discharge pending which will occur first).

  • Recombinant humanThrombomodulin( rhTM)Drug

    Recombinant human thrombomodulin (rhTM) 0.06 mg/kg/j IV, for 7 days (or ICU discharge, pending which will occur first).

  • SivelestatDrug

    0.2 mg/kg/h for 7 days (or ICU discharge, pending which will occur first)

  • Usual careOther

    Usual care

  • blood purification with MTx.100 Plasma Adsorption ColumnOther

    up to 4 hours a day, up to four days in a row

  • G-CSF filgrastimDrug

    0.5 MIU (5μg)/kg/day subcutaneously for 5 consecutive days (or up to ICU discharge pending which occurs first) - same for adults and children .

  • Interferon gamma-1bDrug

    rhIFNg subcutaneously at 50 µg/m2 if body surface \>0,5 m2, or 1.5µg/kg if body surface of 0,5 m2or less, every other day for 15 days (or up to ICU discharge pending which occurs first)

  • FludrocortisoneDrug

    50µg orally (or via the gastric tube) once a day for 7 days (or ICU discharge pending which will occur first) (same for adults and children)

  • Prophylactic unfractionated heparin (UFH)Drug

    100 IU/kg/24h for 6 days

  • Octaplas LGDrug

    12 mL/kg on day 1; repeated daily from day 2 to day 5, provided that PT/INR remains ≥ 1.40 (This intervention will be opened for randomisation once a supply circuit is in place)

  • PlasminogenDrug

    2,2 mg/kg/day (intravenous infusion) during 3 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortalityTime frame: At day 28
  2. Number of days alive without persistent life-supportive therapiesTime frame: At day 28

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Dijon - infectiologie

    Dijon, France · Recruiting

  • CHU Dijon - réanimation adulte

    Dijon, France · Recruiting

  • CH Sud Essonne - site d'Etampes - Réanimation adulte

    Étampes, France · Not yet recruiting

  • Hôpital Raymond Poincaré - infectiologie

    Garches, France · Recruiting

  • Hôpital Raymond Poincaré

    Garches, France · Recruiting

  • CH de Haguenau

    Haguenau, France · Recruiting

  • CHD Vendée - infectiologie

    La Roche-sur-Yon, France · Recruiting

  • CHD Vendée - réanimation adulte

    La Roche-sur-Yon, France · Recruiting

  • CH Le Mans - Réanimation adulte

    Le Mans, France · Not yet recruiting

  • CHRU Nancy - Hôpital Central - Réanimation adulte

    Nancy, France · Recruiting

  • CHU Nantes - Hôpital Hôtel Dieu - Infectiologie

    Nantes, France · Not yet recruiting

  • CHU Nantes - Hôpital Hôtel Dieu - Réanimation adulte

    Nantes, France · Not yet recruiting

  • AP-HP Hôpital Bichat - Réanimation adulte

    Paris, France · Recruiting

  • AP-HP Hôpital Bicêtre - Infectiologie

    Paris, France · Not yet recruiting

  • AP-HP Hôpital Bicêtre - Réanimation adulte

    Paris, France · Not yet recruiting

  • Hôpital Saint Antoine AP-HP - infectiologie

    Paris, France · Recruiting

  • Hôpital Saint Antoine AP-HP - réanimation adulte

    Paris, France · Recruiting

  • CHU Strasbourg - Hôpital Civil (NHC) - Réanimation adulte

    Strasbourg, France · Not yet recruiting

  • CH Tourcoing

    Tourcoing, France · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.